Vaxart, Inc.
VXRT
$0.3181
-$0.0258-7.50%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
4/20/2025
-
Zero Hedge
4/16/2025
-
GuruFocus
4/16/2025
-
Globe Newswire
4/16/2025
-
Globe Newswire
3/31/2025
-
MarketBeat
3/28/2025
-
MarketBeat
3/27/2025
-
TipRanks Financial Blog
3/27/2025
-
The Fly
3/27/2025
-
GuruFocus
3/27/2025
-
TipRanks Financial Blog
3/27/2025
-
The Fly
3/27/2025
-
Globe Newswire
3/24/2025
-
Insider Monkey
3/22/2025
-
Simply Wall St
3/21/2025
-
MarketBeat
3/21/2025
-
MarketBeat
Vaxart Inc Reports Q4 EPS of -$0.12, Missing Estimates; Revenue at $19.5 Million, Below Expectations
3/21/2025
-
GuruFocus
3/21/2025
-
FierceBiotech.com - Biotech
3/21/2025
-
GuruFocus
3/21/2025
-
GuruFocus
3/20/2025
-
SeekingAlpha
3/20/2025
-
Seeking Alpha: Transcripts
3/20/2025
-
Zacks Investment Research
3/20/2025
-
GuruFocus
3/20/2025
-
SeekingAlpha.com: All News
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, March 20, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
650 550 3500
Address
170 Harbor Way
South San Francisco, CA 94080
South San Francisco, CA 94080
Country
Year Founded
--
Business Description
Sector
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral...
more